Bacitracin - Kasten

Drug Profile

Bacitracin - Kasten

Alternative Names: Bactracin

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kasten
  • Class Antibacterials; Cyclic peptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Bacterial infections

Most Recent Events

  • 08 Feb 2017 Chemical structure information added
  • 06 Dec 2016 Early research in Bacterial infections in USA (unspecified route)
  • 06 Dec 2016 Kasten, Inc. sub-licensed the intellectual property and data of bacitracin for the prevention and treatment of drug resistant bacterial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top